Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder

International Journal of Urology

Volumn 17, Issue 9, 2010, Pages 796-800

  Tanaka, Yoshinori ^a   Masumori, Naoya ^b   Tsukamoto, Taiji ^b  

^a Hokkaido Prefectural Esashi Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

overactive bladder; solifenacin; urodynamics

Indexed keywords

CARBON DIOXIDE; SOLIFENACIN;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER FILLING; BLADDER PRESSURE; CLINICAL TRIAL; CYSTOMETRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RESIDUAL URINE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; URODYNAMICS; WOMEN'S HEALTH; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 77956032957     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02602.x     Document Type: Article

References (16)

1. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 87 : 760 766.
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003 20 : 327 336.
3. Homma Y, Yamaguchi O, Hayashi K. (Neurogenic Bladder Society Committee) An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005 96 : 1314 1318.
4. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002 21 : 167 178.
5. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004 93 : 303 310.
6. Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007 100 : 579 587.
7. Ohtake A, Saitoh C, Yuyama H et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol. Pharm. Bull. 2007 30 : 54 8.
8. Suzuki M, Ohtake A, Yoshino T et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur. J. Pharmacol. 2005 512 : 61 6.
9. Ohtake A, Ukai M, Hatanaka T et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. 2004 492 : 243 250.
10. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharmacol. 2002 366 : 97 103.
11. 2+ mobilization study in monkey cells. Life Sci. 2004 74 : 843 853.
12. Ronchi P, Gravina GL, Galatioto GP et al. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol. Urodyn. 2009 28 : 52 7.
13. Homma Y, Yoshida M, Seki N et al. Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 2006 68 : 318 323.
14. Wyndaele JJ, De Wachter S. Cystometrical sensory data from a normal population: comparison of two groups of young healthy volunteers examined with 5 years interval. Eur. Urol. 2002 42 : 34 8.
15. Yamaguchi O, Honda K, Nomiya M et al. Defining overactive bladder as hypersensitivity. Neurourol. Urodyn. 2007 26 : 904 907.
16. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor-Which is the main mechanism of action? Eur. Urol. 2003 43 : 1 5.